Dianthus Therapeutics
Dianthus Therapeutics' revenue fell 67.3% to $2 million in fiscal 2025. Its operating margin was −8,739.3%, down from −1,633.7% a year earlier. Free cash flow was −$129 million. The diluted share count rose 15.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Dianthus Therapeutics does
Dianthus Therapeutics is a clinical-stage biotechnology company, which means it is testing its medicines in people and has none approved for sale. It is working on treatments for severe autoimmune diseases, in which the immune system attacks the body's own tissue.
Its lead candidate, claseprubart, is an antibody that blocks one active part of the complement system, a branch of the immune system that can cause damage in these diseases. The company designed it to be given less often, as an injection patients can give themselves with a pre-filled pen. Dianthus believes it could be used for many complement-driven diseases.
Its second candidate, DNTH212, is a fusion protein that targets two immune pathways at once, one involving interferon production and one involving B cells. It is also designed for self-injection.
Dianthus has a limited operating history and has not finished any late-stage clinical trial. It says it will need substantial new capital to fund its work.
Its biggest risks, as it describes them
- It has no approved products, a limited operating history and has not finished a late-stage clinical trial.
- It will need substantial additional capital, and may not be able to raise it on acceptable terms.
- It has lost money since it began and expects more losses for the foreseeable future.
- It depends heavily on the success of one candidate, claseprubart, and its planned trials.
- Its approach to finding and developing medicines is unproven, and competitors are working on the same diseases.
Income statement
Dianthus Therapeutics lost money in fiscal 2025: a net loss of $162 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 177 | 76 | 131 | 22 | 50 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 16.6x | 10.0x | 18.4x | 15.2x | 13.3x |
| Quick ratio | 16.6x | 10.0x | 18.4x | 15.2x | 13.3x |
Cash flow
Projections
Project Dianthus Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Dianthus Therapeutics says to expect
- Cash position: expected runway
Approximately $1.2 billion of cash, cash equivalents and investments as of September 30, 2026, is projected to provide runway into 2030.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Dianthus Therapeutics shares on the open market, and 8 insiders sold $79.2 million, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | Ryan SavitzEVP, CFO & Cbo | Sold plan | 17,724 | $90.56 | $1.6 million | Form 4 |
| Nov 11, 2026 | Ryan SavitzEVP, CFO & Cbo | Sold plan | 3,044 | $90.03 | $274,051 | Form 4 |
| Nov 10, 2026 | Ryan SavitzEVP, CFO & Cbo | Sold plan | 2,561 | $90.14 | $230,849 | Form 4 |
| Nov 9, 2026 | Ryan SavitzEVP, CFO & Cbo | Sold plan | 100,713 | $90.54 | $9.1 million | Form 4 |
| Sep 17, 2026 | Edward CarrChief Accounting Officer | Sold plan | 20,000 | $101.38 | $2.0 million | Form 4 |
| Sep 1, 2026 | Simrat RandhawaEVP, Head of R&D | Sold plan | 23,124 | $106.41 | $2.5 million | Form 4 |
| Aug 19, 2026 | Simon ReadDirector | Sold plan | 2,778 | $117.55 | $326,554 | Form 4 |
| Aug 10, 2026 | Adam M VenessSVP, General Counsel and Sec. | Sold plan | 16,167 | $110.38 | $1.8 million | Form 4 |
| Aug 10, 2026 | Anne McGeorgeDirector | Sold plan | 7,750 | $109.01 | $844,822 | Form 4 |
| Aug 10, 2026 | Simon ReadDirector | Sold plan | 2,777 | $109.55 | $304,232 | Form 4 |
| Aug 7, 2026 | Marino GarciaCEO and President, Director | Sold plan | 166,000 | $108.11 | $17.9 million | Form 4 |
| Aug 7, 2026 | Adam M VenessSVP, General Counsel and Sec. | Sold plan | 3,833 | $110.70 | $424,319 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | −1,134.9% | −6,416.7% |
| Altman Z'' | 19.54 | 18.44 | 14.17 |
| Accruals ratio | −5.1% | −2.5% | −7.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Pass | Fail |
| F-score | — | — | — |
Compare
Put Dianthus Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics | FY25 | −67.3% | −8,739.3% | −6,349.4% | — | — | — | |
| Immunome | FY25 | −23.2% | −3,228.8% | −2,890.1% | — | — | — | Compare |
| Ovid Therapeutics | FY25 | 1,181.3% | −585.2% | −528.6% | — | — | — | Compare |
| Xenon Pharmaceuticals | FY25 | — | −4,974.3% | −3,732.2% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 3 | 6 | 2 |
| Revenue growth | — | — | — | — | — | — | — | — | 120.6% | −67.3% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 6 | 28 | 41 | 59 | 51 | 47 | 29 | 33 | 83 | 146 |
| Operating income | −9 | −36 | −60 | −83 | −79 | −75 | −30 | −48 | −102 | −178 |
| Net income | −9 | −36 | −58 | −77 | −75 | −71 | −28 | −44 | −85 | −162 |
| Diluted EPS (US$) | −65.15 | −19.12 | −3.13 | −2.07 | −1.71 | −1.29 | −32.57 | −8.45 | −2.55 | −4.20 |
| Diluted shares (millions) | 0 | 2 | 18 | 37 | 44 | 55 | 1 | 5 | 33 | 39 |
| Cash flow | ||||||||||
| Cash from operations | −6 | −22 | −42 | −57 | −64 | −60 | −29 | −37 | −78 | −129 |
| Capital expenditure | 0 | 2 | 8 | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow | −7 | −24 | −50 | −60 | −64 | −61 | −29 | −37 | −78 | −129 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 2 | 11 | 10 | 10 | 10 | 2 | 3 | 13 | 23 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 4 | 51 | 143 | 146 | 149 | 177 | 76 | 131 | 22 | 50 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | — | 54 | 157 | 162 | 162 | 190 | 83 | 179 | 374 | 531 |
| Total liabilities | — | 4 | 12 | 20 | 18 | 17 | 10 | 10 | 22 | 38 |
| Shareholders' equity | −9 | −42 | 146 | 141 | 144 | −17 | −44 | 169 | 352 | 493 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | −1,704.7% | −1,633.7% | −8,739.3% |
| Net margin | — | — | — | — | — | — | — | −1,541.2% | −1,362.8% | −7,973.3% |
| Free cash flow margin | — | — | — | — | — | — | — | −1,308.2% | −1,255.6% | −6,349.4% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | −1,134.9% | −6,416.7% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −111.1% | −53.5% | −52.6% | −112.3% | — | −70.0% | −32.6% | −38.4% |
| Return on assets | — | — | −54.3% | −48.2% | −46.4% | −40.5% | −20.9% | −33.2% | −30.7% | −35.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |